Compounds > lipoxin a4

lipoxin a4 and triazoles

lipoxin a4 has been researched along with triazoles in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bratt, J; Lerner, R; Palmblad, J; Ringertz, B1
Bajaj, M; Birnbaum, Y; Castillo, AC; Ling, S; Perez-Polo, JR; Qian, J; Ye, H; Ye, Y1
Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y1

Other Studies

3 other study(ies) available for lipoxin a4 and triazoles

ArticleYear
Mechanisms for lipoxin A4 induced neutrophil dependent cytotoxicity for human endothelial cells.
    Advances in prostaglandin, thromboxane, and leukotriene research, 1995, Volume: 23

    Topics: Azepines; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Hydroxyeicosatetraenoic Acids; Kinetics; Leukotriene B4; Lipoxins; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Platelet Activating Factor; Superoxide Dismutase; Tetradecanoylphorbol Acetate; Triazoles; Umbilical Veins; Virulence Factors, Bordetella

1995
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.
    Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:6

    Topics: Animals; Blood Glucose; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Immunoblotting; Lipids; Lipoxins; Male; Membrane Proteins; Mice; Myocardial Infarction; Myocardium; Phosphodiesterase 3 Inhibitors; PTEN Phosphohydrolase; Tetrazoles; Triazoles

2012
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
    Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:9

    Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation

2014